A personalized mRNA vaccine plus Keytruda cut the risk of melanoma recurrence or death by 42% in a Phase 3 trial. Overall survival data are not yet mature.
Personalized mRNA Melanoma Vaccine Cut Recurrence or Death Risk 42% in Phase 3 Trial, but Survival Data Pending
by | Oct 24, 2026 | Uncategorized | 0 comments
Recent Comments